GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2011

The Research Foundation of SUNY to Help Sunshine Biopharma Push Anticancer Agent into the Clinic

  • Sunshine Biopharma and The Research Foundation of the State University of New York (SUNY) will work together to develop the former’s lead compound, Adva-27a, for breast cancer and prostate cancer. They will work to take the drug through various stages of preclinical development as well as Phase I trials.

    The Research Foundation of SUNY is acting for and on behalf of Binghamton University. The agreement spans three years and shall be renewed automatically for additional one-year periods until the project is completed.

    Adva-27a is a small molecule that inhibits topoisomerase II. This enzyme is found in abundance in multidrug resistant breast cancer as well as in other types of aggressive cancer, according to Sunshine Biopharma and The Research Foundation of SUNY.

    “Data published in our issued and pending patent applications have shown that Adva-27a is three times more effective in arresting cancer cell growth than its current market competitor,” according to Steve Slilaty, Sunshine’s president and CEO. “We anticipate completion by the first half of 2012, and if things go as we expect we anticipate Adva-27a to be available for compassionate use by the end of the trial.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »